Evaxion Biotech A/S logo

Evaxion Biotech A/S (EVAX)

Market Closed
11 Feb, 20:00
NASDAQ (CM) NASDAQ (CM)
$
2. 78
+0.16
+6.11%
Pre Market
$
2. 75
-0.03 -1.08%
9.68M Market Cap
- P/E Ratio
0% Div Yield
466,800 Volume
-2.08 Eps
$ 2.62
Previous Close
Day Range
2.57 2.9
Year Range
2.22 23.7
Earnings results expected in 41 days

Summary

EVAX closed today higher at $2.78, an increase of 6.11% from yesterday's close, completing a monthly decrease of -35.35% or $1.52. Over the past 12 months, EVAX stock lost -35.35%.
EVAX is not paying dividends to its shareholders.
The last earnings report, released on Dec 17, 2024, exceeded the consensus estimates by 0.31%. On average, the company has surpassed earnings expectations by 0.32%, based on the last three reports. The next scheduled earnings report is due on Mar 25, 2025.
Evaxion Biotech A/S has completed 3 stock splits, with the recent split occurring on Jan 14, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track EVAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

EVAX Chart

FAQ

What Is the Evaxion Biotech A/S(EVAX) Stock Price Today?

The EVAX stock price today is $2.78.

What Stock Exchange Does Evaxion Biotech A/S Trade On?

Evaxion Biotech A/S is listed and trades on the NASDAQ (CM).

What Is the Stock Symbol for Evaxion Biotech A/S?

The stock symbol for Evaxion Biotech A/S is "EVAX".

Does Evaxion Biotech A/S Pay Dividends? What's The Current Dividend Yield?

EVAX is not paying dividends to its shareholders.

What Is the Evaxion Biotech A/S Market Cap?

As of today, Evaxion Biotech A/S market cap is 9.68M.

What is Evaxion Biotech A/S Earnings Per Share?

The Evaxion Biotech A/S EPS is 0.

What Is the Next Evaxion Biotech A/S Earnings Date?

Evaxion Biotech A/S will release its next earnings report on Mar 25, 2025.

Did Evaxion Biotech A/S had any splits?

Evaxion Biotech A/S had 3 splits and the recent split was on Jan 14, 2025.

Evaxion Biotech A/S Profile

Biotechnology Industry
Healthcare Sector
Mr. Christian Kanstrup M.Sc. CEO
NASDAQ (CM) Exchange
US29970R1059 ISIN
US Country
49 Employees
- Last Dividend
22 Jan 2024 Last Split
5 Feb 2021 IPO Date

Overview

Evaxion Biotech A/S represents a forefront clinical-stage biotech entity distinguished by its specialized focus on the development of immunotherapies powered by artificial intelligence. Incorporated in 2008 and having its foundations in Horsholm, Denmark, the company is pioneering in the research and development of novel treatments targeting a range of cancers and infectious diseases. By leveraging the potential of AI, Evaxion Biotech A/S aims to enhance the precision and effectiveness of immunotherapies, paving the way for significant advancements in medical treatments.

Products and Services

Evaxion Biotech A/S boasts an extensive portfolio concentrated on immunotherapies and vaccines, each at varying stages of clinical and pre-clinical development. The following outlines their primary products and services:

  • EVX-01: A cutting-edge cancer immunotherapy that is currently undergoing a clinical Phase IIb trial focusing on metastatic melanoma. EVX-01 utilizes the body's immune system to target and destroy cancer cells, representing a potential leap forward in melanoma treatment.
  • EVX-02: This is a DNA-based cancer immunotherapy in a Phase 1/2a trial for adjuvant melanoma. By encoding antigens that are specifically expressed on melanoma cells, EVX-02 aims to stimulate an immune response targeted at eradicating these cancer cells.
  • EVX-03: As a DNA-based immunotherapy, EVX-03 targets the treatment of various cancers through a patient-specific approach. This strategy holds the promise of tailoring treatments to an individual’s cancer profile, offering a highly personalized therapy option.
  • EVX-B1: In the pre-clinical stage, EVX-B1 is a vaccine candidate designed to combat bacterial diseases. Leveraging the body's immune response to bacterial pathogens, this vaccine aims to provide a robust protective shield against multiple bacterial infections.
  • EVX-B2: Similar to EVX-B1, this vaccine is also in the pre-clinical phase and is aimed at treating other bacterial diseases not covered by EVX-B1. Through meticulous research and development, EVX-B2 seeks to expand the spectrum of bacterial infections that can be effectively prevented.
  • EVX-V1: This pre-clinical stage vaccine targets viral diseases, harnessing the power of the immune system to prevent infections from a range of viruses. With the ongoing threat of viral pandemics, EVX-V1 represents a vital component of Evaxion Biotech A/S’s endeavor to combat viral diseases globally.

Contact Information

Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970
Phone: 45 53 53 18 50